Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives.
Roberto MinaStefania OlivaMario BoccadoroPublished in: Journal of clinical medicine (2020)
Minimal residual disease (MRD) detection represents a sensitive tool to appropriately measure the response obtained with therapies for multiple myeloma (MM). The achievement of MRD negativity has superseded the conventional complete response (CR) and has been proposed as a surrogate endpoint for progression-free survival and overall survival. Several techniques are available for the detection of MRD inside (next-generation sequencing, flow cytometry) and outside (PET/CT, magnetic resonance) the bone marrow, and their complementary use allows a precise definition of the efficacy of anti-myeloma treatments. This review summarizes MRD data and results from previous clinical trials, highlights open issues related to the role of MRD in MM and discusses how MRD could be implemented in clinical practice to inform on patient prognosis and drive therapeutic decisions.
Keyphrases
- multiple myeloma
- pet ct
- free survival
- magnetic resonance
- flow cytometry
- bone marrow
- clinical trial
- clinical practice
- mesenchymal stem cells
- loop mediated isothermal amplification
- minimally invasive
- magnetic resonance imaging
- gene expression
- randomized controlled trial
- electronic health record
- real time pcr
- deep learning
- study protocol
- phase ii
- sensitive detection